Company intelligence / Profile preview

Sobrera Pharma

Gothenburg, Sweden

Ownership: Private
Development stage: Other

Overview

Sobrera Pharma is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for Alcohol Use Disorder (AUD). The company's lead candidate, SO-001, is a dopamine stabilizer designed to reduce alcohol cravings and consumption by modulating the brain's reward system. Sobrera Pharma aims to address the significant unmet medical need in addiction medicine through evidence-based pharmacological interventions. The company is currently advancing its lead program through Phase 2 clinical trials to demonstrate efficacy and safety in patients with moderate to severe AUD.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

SO-001

Unknown

Beyond the preview

Go deeper on Sobrera Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sobrera Pharma.

Explore the full profile